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There is considerable interest in the development of broadly protective inﬂuenza vaccines because of the continuous emergence
of antigenic drift variants of seasonal inﬂuenza viruses and the threat posed by the emergence of antigenically distinct pandemic
inﬂuenza viruses. It has been recognized more than three decades ago that inﬂuenza A virus-speciﬁc cytotoxic T lymphocytes
recognize epitopes located in the relatively conserved proteins like the nucleoprotein and that they cross-react with various
subtypes of inﬂuenza A viruses. This implies that these CD8+ T lymphocytes may contribute to protective heterosubtypic
immunity induced by antecedent inﬂuenza A virus infections. In the present paper, we review the evidence for the role of virus-
speciﬁc CD8+ T lymphocytes in protective immunity against inﬂuenza virus infections and discuss vaccination strategies that aim
at the induction of cross-reactive virus-speciﬁc T-cell responses.
1.Introduction
Every year, inﬂuenza A viruses (IAVs) cause epidemic
outbreaks of respiratory tract infection resulting in excess
morbidity and mortality. Especially individuals with cer-
tain underlying medical conditions and the elderly are at
risk for complications of inﬂuenza.Therefore, it is recom-
mended to vaccinate these individuals against inﬂuenza
annually.
Currently used vaccines largely aim at the induction of
antibodies directed to viral glycoproteins, in particular the
hemagglutinin (HA). These antibodies neutralize the virus
by preventing viral attachment to host cells and are generally
considered the main correlate of protection against inﬂuenza
virus infection [1]. Therefore, assessing postvaccination HA-
speciﬁc antibody titers is used as surrogate marker for
vaccine eﬃcacy compliant with EMEA and FDA guidelines
[2, 3].
However, seasonal inﬂuenza viruses continuously accu-
mulate amino acid substitutions in the antigenic sites of the
HA molecules and consequently display considerable anti-
genic drift.
This allows currently circulating inﬂuenza viruses to
escape from the neutralizing activity of antibodies induced
by previous infections or vaccination and necessitates updat-
ing the vaccine regularly to match recent epidemic strains.
Occasionally, novel strains of inﬂuenza A viruses are
introduced with HA molecules that are antigenically distinct
from seasonal inﬂuenza A viruses including those of a novel
subtype. Seasonal inﬂuenza vaccines are not protective
against these new viruses, which may spark a pandemic out-
break of inﬂuenza and against which speciﬁc vaccines need
to be developed. The pandemic of 2009 caused by inﬂuenza
A/H1N1 viruses of swine origin painfully highlighted that
the development of a matching vaccine is a time consuming
process, and, in many countries, vaccines became available
after the peak of pandemic [4, 5].
For these reasons, there is considerable interest in the
development of more broadly protective inﬂuenza vaccines2 Journal of Biomedicine and Biotechnology
that ideally would aﬀord broad protection against various
subtypes of inﬂuenza A viruses [6, 7] and/or antigenic drift
variants within a subtype.
It has been well established that infection with inﬂuenza
A virus can induce a certain degree of protective immunity
to infection with other inﬂuenza A viruses of unrelated
subtypes (heterosubtypic immunity) (for review see [8]).
Elucidation of the correlates of protection of this type
of immunity may aid the development of more universal
vaccines. Since diﬀerent subtypes of inﬂuenza A virus are
deﬁned by the absence of serological cross-reactivity, it is
unlikely that antibodies to HA or neuraminidase (NA) con-
tribute to this type of infection-induced immunity to a great
extent. However, recently antibodies have been identiﬁed
speciﬁc for epitopes located in the stem region of the HA
molecule, displaying broad reactivity and broad neutralizing
activity against several diﬀerent inﬂuenza A viruses of diﬀer-
e n tH As u b t y p e s[ 9–16]. HA-stem-based vaccines may be a
promising venue for the development of broadly protective
vaccines. Other vaccine candidates aiming at the induction
ofcross-protectiveantibodiesmayincludethosebasedonthe
M2protein[17–21].TheinductionofM2-speciﬁcantibodies
after infection is rather ineﬃcient. Furthermore, several
studies have shown that postinfection serum does not aﬀord
protection against a heterosubtypic strain of inﬂuenza A
virus, whereas virus-speciﬁc T cells do [22]. Nevertheless,
induction of M2-speciﬁc antibodies after M2 hyperimmu-
nization does aﬀord heterosubtypic immunity. However,
it was shown that the protection mediated by vaccine-
induced M2 antibodies was weak and could not prevent
infection of mice. The mechanism of protection was based
on antibody-dependent cell cytotoxicity (ADCC) [23].
Since the majority of virus-speciﬁc T cells, and in
particularCD8+ cytotoxicTlymphocytes(CTL),aredirected
against relatively conserved viral proteins like the nucleo-
protein (NP) and the matrix 1 protein (M1), it was already
suggested three decades ago that virus-speciﬁc CTLs con-
tribute to heterosubtypic immunity [24, 25]. In the present
paper, we review the evidence that inﬂuenza virus-speciﬁc T
cells contribute to (cross-)protective immunity and discuss
vaccine formulation that can induce virus-speciﬁc CTL.
2. CTLs Contribute to
Heterosubtypic Immunity
The most important mode of action of virus-speciﬁc CTL
is recognition and elimination of virus-infected cells. This
way, the production of progeny virus is prevented. Thus,
the presence of preexisting T-cell immunity results in more
rapid clearance of virus infections. Key for heterosubtypic
immunity is that CTLs are cross-reactive and recognize
epitopes shared by inﬂuenza A viruses of diﬀerent subtypes.
The eﬀectors functions of CTLs that are responsible for
the elimination of virus-infected cells include the release of
perforin and granzyme from their granules and Fas/FasL
interactions with infected target cells. In addition, upon acti-
vation virus-speciﬁc CD8+ Tc e l l sc a np r o d u c eav a r i e t yo f
diﬀerentcytokinesincludingIFN-γ andTNF-α.Itwasshown
that virus-speciﬁc CTLs, through their receptor recognize
viral peptides, which are generated by the endogenous route
of antigen processing and that are ultimately presented by
MHC class I molecules on the surface of antigen-presenting
cells or virus-infected cells [26, 27]. For the eﬃcient induc-
tion of virus-speciﬁc CTLs, it is required that the antigen
is present in the cytosol of antigen-presenting cells where
antigen processing takes place.
Inﬂuenza virus-speciﬁc CTL can recognize epitopes that
are shared by diﬀerent subtypes of inﬂuenza A virus. Indeed,
it was shown that a large proportion of mouse and human
CTLs induced after infection with inﬂuenza A virus were
directed against the relatively conserved NP and M1 protein
[29, 31, 37–39]. This raised the expectation that these cells
contribute to cross-protection against viruses of diﬀerent
subtypes.
Many studies have been performed to demonstrate the
cross-reactivity of inﬂuenza virus-speciﬁc CTLs and their
role in heterosubtypic immunity. The outcomes of these
studies are summarized in Table 1.
2.1. Evidence for Cross-Reactivity of CTL In Vitro. Early
evidence for the intersubtypic cross-reactivity of CTL was
described by Zweerink et al. [28, 40], who demonstrated that
mouse CTL speciﬁc for inﬂuenza virus of the H2N1 subtype
could lyse target cells infected with virus of the H3N2
subtype.
Also with other combinations of subtypes, the cross-re-
active nature of virus-speciﬁc CTL was conﬁrmed (Table 1).
For example, it was shown that in healthy individuals, with a
history of infection with seasonal inﬂuenza virus, memory
CD8+ T cells were present in the blood that cross-reacted
with highly pathogenic H5N1 virus [32–34]. The presence of
cross-reactive CTL may aﬀord a certain degree of protection
against infection with these viruses, which still constitute
a pandemic threat. It is of interest to note that especially
younger individuals are at risk for severe disease and fatal
outcome of inﬂuenza H5N1 infection [41]. It is tempting
to speculate that younger individuals less likely have been
exposed to seasonal inﬂuenza A viruses of the H3N2 or
H1N1 subtype and, thus, have not mounted a CTL response
to these viruses. Therefore, they may be more susceptible to
infection with a virus of an alternative subtype. However,
it cannot be ruled out that other factors play a role in the
observed disproportionate age distribution of severe H5N1
cases. Furthermore, CTL obtained from healthy subjects
before the pandemic of 2009 displayed cross-reactivity with
the pandemic 2009 pH1N1 virus [35, 36], which may have
aﬀorded a certain degree of protection against this virus.
2.2. Evidence for the Role of CTL in Protection against Infec-
tion. Evidence for the role of virus-speciﬁc CTL in protec-
tion against inﬂuenza virus infection predominantly stems
from animal models (Table 2). Using various combinations
of inﬂuenza A virus subtypes, it was demonstrated that CTL
responses induced after a primary infection with inﬂuenza
virus either correlated with protection against challenge
infection with a virus of another subtype or were responsibleJournal of Biomedicine and Biotechnology 3
Table 1: Evidence for cross-reactivity of inﬂuenza virus-speciﬁc CTL.
Subtype
Comments Ref.
Priming subtype Cross-reaction with Species
H2N1 H3N2 Mouse Cross-reactivity conﬁrmed in Cr-release assays using
cultured splenocytes of primed mice [28]
H1N1 H2N2
H3N2 Mouse Cross-reactivity conﬁrmed in Cr-release assays using
splenocytes of primed mice [24]
H3N2 H1N1 Mouse Target cells expressing NP from H1N1 recognized by
cultured splenocytes from primed mice [29]
H3N2 H1N1 Mouse Cross-reactive cultured splenocytes recognize inner proteins
of inﬂuenza A virus [30]
H3N2 H1N1 Human Cross-reactive CTLs recognize NP, M1, or PB2 [31]
Seasonal
inﬂuenza H5N1 Human Cross-reactive CTLs were detected in the blood of healthy
human subjects not exposed to H5N1 virus [32–34]
pH1N1 H1N1 Human
T cells speciﬁc for the NP418 epitope induced by the 2009
pH1N1 cross-react with the 1918-H1N1 variant but not with
contemporary variants
[35]
Seasonal
inﬂuenza 2009 pH1N1 Human Cross-reactive CTLs were detected in the blood of healthy
human subjects not exposed to 2009 pH1N1 virus [36]
for protective immunity [8, 42–47] .T h ef u l le x t e n to fc r o s s -
reactivity of human CTL is not known. However, since the
conserved proteins like the NP, M1, and the polymerase
proteins display a high degree of sequence homology,
it is assumed that the extent of cross-reactivity between
diﬀerent subtypes of inﬂuenza A virus is substantial. This is
exempliﬁed by demonstrating that human CTLs directed to
human inﬂuenza A viruses of the H3N2 subtype cross-react
considerably with avian inﬂuenza A viruses of the H5N1
subtype [42].
By adoptive transfer or depletion of virus-speciﬁc CD8+
T cells, it was conﬁrmed that these cells contributed to
protective heterosubtypic immunity [22, 48–50, 52]. Indeed,
theadoptivetransferofvirus-speciﬁcCTLstona¨ ıverecipient
mice had a beneﬁcial eﬀect on the course of subsequent
challenge infections. It was shown that transfer of CTL from
mice infected with seasonal H3N2 virus protected recipient
mice against challenge infection with 2009 pH1N1 virus
[22]. Also chickens that received CTL from chickens infected
with H9N2 virus were protected against subsequent chal-
lenge infection with highly pathogenic H5N1 virus [56].
Also, depletion of CD8+ T cells prior to challenge infection
conﬁrmed that these cells contribute to heterosubtypic
immunity. Primed mice or chickens, from which CTL were
depleted, had higher lung virus titer, developed more severe
disease, and displayed higher mortality rates after challenge
infection than control animals [54, 55, 57, 59].
There is little evidence that CTLs contribute to hetero-
subtypic immunity in humans. The ﬁrst and, to our knowl-
edge, the only evidence for this was described by McMichael
et al. They demonstrated that in experimentally infected
individuals, virus-speciﬁc cytotoxicity inversely correlated
withtheextent of virusshedding in theabsenceof antibodies
speciﬁc for the H1N1 strain that was used for infection [38].
There is, however, epidemiological evidence that indicate
thatpriorexposuretoinﬂuenzavirusesisinducingprotective
immunity against a heterosubtypic strain of inﬂuenza [60].
People, who experienced symptomatic inﬂuenza caused by
infection with inﬂuenza viruses of the H1N1 subtype, were
partially protected from infection with the pandemic H2N2
viruses in 1957 [60]. A possible correlation with the presence
of virus-speciﬁc CTL-mediated immunity was not studied.
More circumstantial evidence is based on the observation
that the ratio between synonymous and nonsynonymous
(Ds/Dn) mutations in the NP gene is lower in CTL epitope
sequences than in the rest of the protein. This also provides
indirectevidencethatCTLsexertantiviralactivityinhumans
at the population level [61] and indicates that CTL epitopes
are under selective pressure. Indeed, a number of amino
acid substitutions that were observed in CTL epitopes during
the evolution of inﬂuenza A/H3N2 viruses were associated
with escape from recognition by virus-speciﬁc CTL [61–
65]. Examples include the R384G substitution at the anchor
residueoftheHLA-B∗2705restrictedNP383–391 epitopeand
amino acid substitutions at T-cell receptor contact residues
of the HLA-B∗3501 restricted NP418–426 epitope. In both
cases, the amino acid substitutions aﬀected the in vitro hu-
man inﬂuenza virus-speciﬁc CTL response signiﬁcantly [66,
67].
Of interest, the R384G substitution alone was detrimen-
tal to viral ﬁtness and was only tolerated in the presence of
two functionally compensating comutations [68, 69].
Thus, apparently, the virus has the capacity to overcome
functionalconstraintsinordertoevadeT-cellimmunity.The
rapid ﬁxation of the R384G substitution could be explained
by strong bottle-neck and founder eﬀects at the population
level in a theoretical model [70]. Although CTL epitopes,
can thus display variability allowing the virus to escape from
recognitionbyCTLspeciﬁcfortheseepitopes,otherepitopes
remain fully conserved including the immunodominant
M158–66 epitope that is restricted by HLA-A∗0201, which
has a high prevalence in most countries. For this and some
other conserved epitopes it was demonstrated that also
functional constraints may play a role in limiting the virus4 Journal of Biomedicine and Biotechnology
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to escape eﬃciently from recognition by CTL to these highly
conserved epitopes [71, 72]. Thus, inﬂuenza virus CTL epi-
topes are either conserved, display variation at non-anchor
residues, or loose their anchor residues at the cost of viral
ﬁtness, which need to be functionally compensated by the
accumulation of comutations.
3. Considerations for Vaccine Development
A large number of peptides are generated during processing
of viral proteins in infected cells, but only some of these pep-
tides are ultimately presented by major histocompatibility
complex class I molecules and recognized by speciﬁc CTL.
The hierarchy of CTL responses is called immunodominance
[73–75] and has been demonstrated in animal models [76]
and humans [77].
In mice it was shown that the hierarchy of primary and
secondary CTL responses diﬀer [76, 78, 79]. Since some
CTL epitopes are more dominant than others, also the HLA
usage of the CTL response is dependent on the repertoire
of viral epitopes. For this reason, the HLA usage of the
CTL response to inﬂuenza A virus is diﬀerent from that to
inﬂuenza B virus [80]. Immunodominance also complicates
the analysis of CTL responses induced by vaccination or
infection. Assessing the response to a single epitope is not
fully informative without knowing it is relative immuno-
dominance. In addition, it has been shown that the response
to a single epitope can be inﬂuenced by other non-
corresponding HLA alleles [77, 81].
The HLA haplotype dictates which epitopes can be
presented and recognized and determines the magnitude of
the virus-speciﬁc CTL response. For example, the immun-
odominant M158–66 epitope is only recognized in HLA-
A∗0201 positive subjects, and, in these individuals, the
overall CTL response to inﬂuenza A virus is higher than
in HLA-A∗0201 negative subjects that are matched for the
remaining HLA alleles [77].
Thus, both immunodominance and HLA restriction of
CTL responses should be taken into account when assessing
the ability of candidate vaccines to induce virus-speciﬁc CTL
responses.
For the eﬃcient induction of CTL responses, it is critical
that viral antigens enter the endogenous route of antigen
processing.Toachievethis,viralproteinsneedtobedelivered
in the cytosol of antigen presenting-cells, where degradation
of these proteins by the proteasome takes place. The peptides
that are generated are then transported by the transporter
associated with antigen processing (TAP) into the endo-
plasmic reticulum where binding of antigenic peptides with
their corresponding MHC class I molecules can take place.
These MHC class I/peptide complexes are subsequently
transported to the cell membrane for recognition by virus-
speciﬁc CD8+ T lymphocytes. The cytosolic delivery of viral
proteinsbyvaccinepreparationscanbeachievedbyusinglive
(attenuated) virus, viral vectors, or expression from plasmid
DNA, which allow de novo synthesis of viral proteins in the
infected cells. Alternatively, particulate antigen presentation
forms can be used which can translocate viral proteins into
the cytosol directly or through endosomal degradation of the
exogenous viral proteins [82].
In addition to CD8+ T cells, CD4+ T cells have been
shown to contribute to heterosubtypic immunity [54, 55].
The relationship between CD4+ and CD8+ T cells has been
studied extensively, and it seems that memory CD8+ Tc e l l s
are impaired in the absence of memory CD4+ T cells leading
to increased cell death and decreased secondary T-cell
response[83].Thus,itisimperativethatvaccinesalsoinduce
adequatevirus-speciﬁcCD4+ T-helpercellresponsesinaddi-
tion to CD8+ T-cell responses. Of interest, also CD4+ Tc e l l s
speciﬁc for seasonal inﬂuenza A viruses display cross-
reactivity with inﬂuenza A viruses of diﬀerent subtypes
including 2009 pH1N1 [84] and H5N1 [32, 34, 85].
Other cells of the adaptive immune system may play a
role in heterosubtypic immunity against inﬂuenza A viruses.
Some studies have indicated that B cells and mucosal anti-
bodies play a role in heterosubtypic immunity [23, 44, 86–
90]. However, we and others were able to adoptively transfer
heterosubtypic immunity with T cells but not with B cells
to na¨ ıve recipient mice (Table 2). Of interest, CD4+ Tc e l l s
are necessary to promote the protective eﬀect of virus-
speciﬁc CD8+ T cells [22]. However, since this special issue
focusrs on CD8+ T, cells we did not discuss the role of other
immune cells extensively. Also cells of the innate immune
system (like NK cells and macrophages) have protective
eﬃcacy; however, since these cells do not develop memory
against pathogens, they cannot be at the basis of vaccination
strategies which aim at the induction of immunological
memory against these pathogens.
4.LiveAttenuatedVaccines
The use of live attenuated inﬂuenza vaccines (LAIVs) is of
interest since it results in viral protein synthesis in infected
antigen-presenting cells which is a prerequisite for the
eﬃcient induction of virus-speciﬁc CTL responses [91–94].
LAIVs also induce antibody responses and, thus, have the
capacity to induce both virus-speciﬁc CTL and B cells which
both contribute to protective immunity. They are currently
used in the United States and in Russia, and request of
approval for their use in Europe has been submitted.
LAIVs have been obtained by adaptation to replicate at
low temperatures (25–33◦C). The use of these cold-adapted
viruses results in mild infections of the upper respiratory
tract only. It has been shown in humans that LAIVs induce
stronger virus-speciﬁc T-cell responses than inactivated
vaccines [94, 95]. Intranasal administration of H3N2 LAIV-
aﬀordedmicepartialprotectionagainstinfectionwithH1N1
virus. LAIV-vaccinated mice that were depleted of CD8+ T
cells were not protected and did not survive H1N1 challenge
infection [96]. Furthermore, seasonal LAIV induced strong
CTL response in mice and aﬀorded protection against 2009
pH1N1 virus whereas an inactivated vaccine did not [97].
Similar ﬁndings were observed by others, and the contri-
bution of T cells in protection against 2009 pH1N1 was
conﬁrmed after depletion of these cells [98].
LAIVs based on nonpathogenic H5N2 viruses also
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H5N1 in mice, which correlated with the induction of cross-
reactive antibodies but also with cross-reactive T cells [99].
Another strategy to attenuate inﬂuenza viruses is to
delete part of the nonstructural protein 1 (NS1) [100–102].
This protein is known to be an antagonist of IFNα.T r u n -
cation of NS1 renders this protein nonfunctional causing
attenuation of the virus [102]. It has been shown in mice
that inﬂuenza virus, with altered NS1 genes induce potent
and protective memory T-cell responses [103].
Also a live attenuated M1 mutant H1N1 virus with an
attenuated phenotype in vivo was generated [104]. This live
attenuated mutant virus also induced broadly cross-reactive
immunity against H3N2 and H5N1 viruses, which was
shown to be based on both humoral and cellular responses
by adoptive transfer experiments.
5.DNA Vaccines
DNA vaccines have the advantage that they can be produced
rapidly and at low cost. DNA vaccines encode for one or
several proteins of inﬂuenza viruses and induce an immune
response targeting the encoded protein [105].
Typically, plasmids are constructed with the gene of
interest, for example, the NP gene, under control of a strong
eukaryoticpromoter,forexample,theCMVpromoter.Upon
immunization of the plasmid by injection, electroporation,
or gene gun delivery, the gene is expressed in cells that
have taken up the plasmid (e.g., myocytes or dendritic cells).
Then,theproteinsaresynthesizedinthecytosolofthesecells.
After processing of these proteins, immunogenic peptides
will be generated and presented by MHC class I molecules
to virus-speciﬁc T cells [106].
The design of DNA vaccine is complex. Over the years,
it has been shown that numerous factors play a role in
the eﬃciency of expression such as the promoter, the G/C
content (sequences rich in C/G are likely to form secondary
structure that inhibit translation), supercoiling that increase
transfectioneﬃciency,polyadenylationthatenhancestability
of mRNA, and codon optimization (for review see [107]).
It has been shown in mice that the administration of
DNA vaccine encoding the NP protein of inﬂuenza induced
a strong CTL response which correlated with protection
againstchallengeinfectionwithhomologousorheterologous
virus [108]. Numerous studies have conﬁrmed these results
with DNA vaccines expressing NP, M1, or HA proteins in
various animal models [109–114]. One study evaluated the
delivery of the vaccine by in vivo electroporation instead of
the classical epidermal route. They showed that, in mice,
ferrets, and nonhuman primates, this route of delivery
induce protective humoral and cellular immunity [115].
Recently, a phase I clinical trial was performed with a
candidate inﬂuenza DNA vaccine. The vaxfectin-adjuvanted
plasmid DNA vaccines encoding inﬂuenza H5 HA, NP, and
M2 were able to elicit T-cell responses against HA in most of
the subjects and against NP and M2 in some of them [116].
Safety remains a concern for DNA vaccination. There
might be a risk of integration into the host genome, which
may increase the risk of malignancies or tolerance induction
[117].
6. VectoredVaccines
Various viruses can be used as viral vectors to deliver foreign
antigens.AsforLAIV,theuseofviralvectorscausedinfection
of cells, which would allow endogenous antigen processing
and MHC class I restricted presentation. Several viruses have
been considered as potential vector vaccine candidates and
were able to induce CTL response such as baculovirus [118],
vesicular stomatitis virus [119, 120], and Semliki Forest virus
[121]. Adenovirus and poxviruses, like modiﬁed vaccinia
virus Ankara (MVA), have been studied extensively for the
delivery of inﬂuenza antigens. The design and production of
such vaccines have been reviewed elsewhere [122–124].
Recombinant adenoviruses that are unable to replicate in
human cells and that encode one or more genes of interest
such as the HA, NP, and M1 genes, can be produced. Using
such recombinant, viruses protective T-cell responses were
induced in mice [21, 125–132] and chickens [132, 133].
Recently, it was also demonstrated that an adenovirus-based
vaccine expressing HA, NP, and M1 of the 2009 pH1N1
virus induced protective humoral and cellular immunity
against homologous challenge and partial protection against
challenge with a heterologous virus [134].
MVA-based inﬂuenza vaccines have been studied in
various animal models extensively [124, 135–137]. These
vector vaccines conferred protection and induced virus-
speciﬁc CTL responses [138–140].
Recently, MVA vectors encoding the NP and M1 genes
were evaluated in a phase I clinical trial and were shown
to be safe and immunogenic. These candidate vaccines also
inducedvirus-speciﬁcCD8+ T-cellresponsesmoreeﬃciently
compared to other vaccination strategies [141].
7.Other Vaccines andAdjuvants
Inadditiontothevaccineformulationdescribedabove,other
vaccine formulations have been described able to induce
virus-speciﬁc CD8+ T-cell responses. For example, virus-like
particles, which can be produced after expressing inﬂuenza
virus antigens in (insect) cells [142], have been shown to
induce CTL responses in mice [143, 144] and in chickens
[145]. Also, with gamma-irradiated inﬂuenza A virus prepa-
rations, protective immunity was induced in mice against
infection with homologous and heterologous inﬂuenza
Aviruses.Adoptivetransferexperimentsshowedthatprotec-
tive immunity was mediated by virus-speciﬁc T cells [146].
Speciﬁc adjuvant systems like immune-stimulating com-
plexes (ISCOMs) can be used for the induction of virus-
speciﬁc CTL responses. ISCOMs consist of cholesterol,
phospholipids, viral proteins, and glycosides of the adjuvant
Q u i lA[ 147]. In addition to enhancing B-cell responses, the
use of ISCOMs also induces strong T-cell responses. Since
ISCOMs also facilitate transport of viral protein into the
cytoplasm of antigen-presenting cells, it also induces CTL
responses [148]. It has been demonstrated in mice that, with
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induced, which correlated with the induction of the virus-
speciﬁc T-cell responses [149, 150]. Also, in humans, virus-
speciﬁc CTL responses could be induced with ISCOM-based
vaccines in addition to antibody responses [151, 152]. For
the formulation of virosomes, the membrane glycoproteins
of inﬂuenza viruses are incorporated into a lipid bilayer
containing phospholipids resulting in vesicles of +/−150nm
in diameter [153]. Since the fusion activity of the HA
molecules is retained, it would allow delivery of antigens (or
plasmid DNA) from the endosomes into the cytosol, allow-
ing the induction of CTL responses [154, 155].
In clinical trials, virosome-based vaccines were more
immunogenic intheelderlythanconventional vaccines[150,
156–158].
8. Conclusions
There is ample evidence that virus-speciﬁc CTLs contribute
to protective immunity against inﬂuenza virus infections.
Because of their cross-reactive nature, virus-speciﬁc CTLs
aﬀord protection against inﬂuenza A viruses of various
subtypes.
It should be realized that antibodies, directed against the
viral envelope proteins HA and NA, are the primary corre-
lates of protection against infection with inﬂuenza A viruses
provided that they match the strain causing the infection.
T h ep r e s e n c eo fs u ﬃciently high titers of speciﬁc serum
antibodies, induced by vaccination or infection, will pro-
tect individuals from a subsequent infection. Under these
circumstances, the induction or presence of virus-speciﬁc
CD8+ T lymphocytes may be redundant. Therefore, the
induction of these antibodies should be the strategy of
choice.However,inthecaseoftheemergenceofdriftvariants
of seasonal viruses, the available vaccines may not be as
eﬃcacious due to a poor antigenic match. In the case of the
introduction of a novel pandemic strain, the seasonal vac-
cines will be poorly protective, and novel pandemic vaccines
need to be produced, which is a time-consuming process.
Underthesecircumstances,inwhichhumoralimmunityfails
to aﬀord protection, the presence of cross-reactive CTL will
not prevent infection but will contribute to more rapid clear-
ance of infection and reduce disease severity and mortality.
Various vaccination formulations aiming at the induction of
virus-speciﬁc CTL are currently under development. Future
preclinical and clinical testing need to provide information
ontheeﬀectivenessofthesevaccines.Inapandemicscenario,
vaccines that induce cross-protective CTL could be used
for emergency vaccination until vaccines become available
that induce antibodies of the proper speciﬁcity. Especially,
immunogenically na¨ ıve subjects, like young children, that
have not previously experienced inﬂuenza virus infection
may beneﬁt from such a strategy.
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